DK2638054T3 - Uracylspirooxetannukleosidphosphoramidater - Google Patents
Uracylspirooxetannukleosidphosphoramidater Download PDFInfo
- Publication number
- DK2638054T3 DK2638054T3 DK11785634.4T DK11785634T DK2638054T3 DK 2638054 T3 DK2638054 T3 DK 2638054T3 DK 11785634 T DK11785634 T DK 11785634T DK 2638054 T3 DK2638054 T3 DK 2638054T3
- Authority
- DK
- Denmark
- Prior art keywords
- hcv
- compound
- added
- mixture
- mmol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (7)
1. Forbindelse med formel (I)
2. Saltform af en forbindelse ifølge krav 1.
3. Saltform ifølge krav 2, hvor saltet er et farmaceutisk acceptabelt salt.
4. Solvatform af en forbindelse ifølge krav 1, 2 eller 3.
5. Farmaceutisk præparat, der omfatter en antiviralt effektiv mængde af en forbindelse ifølge et hvilket som helst af kravene 1 til 4 og et farmaceutisk acceptabelt bæremateriale.
6. Forbindelse ifølge et hvilket som helst af kravene 1 til 4 til anvendelse som en medicin.
7. Forbindelse ifølge et hvilket som helst af kravene 1 til 4 til anvendelse til behandling eller profylakse af HCV-infektion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10190660 | 2010-11-10 | ||
PCT/EP2011/069865 WO2012062870A1 (en) | 2010-11-10 | 2011-11-10 | Uracyl spirooxetane nucleoside phosphoramidates |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2638054T3 true DK2638054T3 (da) | 2015-03-09 |
Family
ID=45002928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11785634.4T DK2638054T3 (da) | 2010-11-10 | 2011-11-10 | Uracylspirooxetannukleosidphosphoramidater |
Country Status (7)
Country | Link |
---|---|
US (1) | US9012428B2 (da) |
EP (1) | EP2638054B1 (da) |
DK (1) | DK2638054T3 (da) |
ES (1) | ES2531583T3 (da) |
PL (1) | PL2638054T3 (da) |
PT (1) | PT2638054E (da) |
WO (1) | WO2012062870A1 (da) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9403863B2 (en) | 2011-09-12 | 2016-08-02 | Idenix Pharmaceuticals Llc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
PE20150132A1 (es) | 2012-05-22 | 2015-02-14 | Idenix Pharmaceuticals Inc | Compuestos d-aminoacidos para enfermedad hepatica |
EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
US9422323B2 (en) | 2012-05-25 | 2016-08-23 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
CN104583224A (zh) * | 2012-07-03 | 2015-04-29 | 百时美施贵宝公司 | 制备用于治疗病毒感染的核苷化合物的富含非对映体的氨基磷酸酯衍生物的方法 |
EP2890704B1 (en) | 2012-08-31 | 2018-02-28 | Novartis AG | 2'-ethynyl nucleoside derivatives for treatment of viral infections |
US9192621B2 (en) | 2012-09-27 | 2015-11-24 | Idenix Pharmaceuticals Llc | Esters and malonates of SATE prodrugs |
AP2015008384A0 (en) | 2012-10-08 | 2015-04-30 | Univ Montpellier Ct Nat De La Rech Scient | 2'-Chloro nucleoside analogs for hcv infection |
WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
EP2970358B1 (en) | 2013-03-04 | 2021-06-30 | Idenix Pharmaceuticals LLC | 3'-deoxy nucleosides for the treatment of hcv |
US20140271547A1 (en) | 2013-03-13 | 2014-09-18 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
KR20220025914A (ko) | 2015-03-06 | 2022-03-03 | 아테아 파마슈티컬즈, 인크. | HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드 |
WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
CN116036114A (zh) | 2016-09-07 | 2023-05-02 | 阿堤亚制药公司 | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 |
KR102592899B1 (ko) | 2017-02-01 | 2023-10-24 | 아테아 파마슈티컬즈, 인크. | C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염 |
CN112351799A (zh) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
CA3174825A1 (en) * | 2020-04-14 | 2021-10-21 | Janssen Pharmaceuticals, Inc. | Spirocyclic nucleoside analogues for the treatment of hepatitis e |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1773355B1 (en) | 2004-06-24 | 2014-06-25 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
DE102005005399A1 (de) | 2005-02-05 | 2006-08-10 | Lts Lohmann Therapie-Systeme Ag | Isolierung von Atrarsäure, Synthese von Atrarsäure-Derivaten sowie deren Verwendung der Atrarsäure und ihrer Derivate zur Behandlung der benignen Prostatahyperplasie und des Prostatakarzinoms |
EP1928475B1 (en) * | 2005-08-15 | 2018-05-23 | Riboscience LLC | Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides |
WO2007095269A2 (en) * | 2006-02-14 | 2007-08-23 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
JO3027B1 (ar) * | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
-
2011
- 2011-11-10 EP EP11785634.4A patent/EP2638054B1/en not_active Not-in-force
- 2011-11-10 PL PL11785634T patent/PL2638054T3/pl unknown
- 2011-11-10 DK DK11785634.4T patent/DK2638054T3/da active
- 2011-11-10 ES ES11785634.4T patent/ES2531583T3/es active Active
- 2011-11-10 PT PT11785634T patent/PT2638054E/pt unknown
- 2011-11-10 US US13/884,852 patent/US9012428B2/en not_active Expired - Fee Related
- 2011-11-10 WO PCT/EP2011/069865 patent/WO2012062870A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
ES2531583T3 (es) | 2015-03-17 |
EP2638054B1 (en) | 2014-12-03 |
EP2638054A1 (en) | 2013-09-18 |
PL2638054T3 (pl) | 2015-05-29 |
US9012428B2 (en) | 2015-04-21 |
PT2638054E (pt) | 2015-03-02 |
US20130244968A1 (en) | 2013-09-19 |
WO2012062870A1 (en) | 2012-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2638054T3 (da) | Uracylspirooxetannukleosidphosphoramidater | |
EP2638053B1 (en) | Uracyl spirooxetane nucleoside phosphoramidates | |
US10544184B2 (en) | Uracyl spirooxetane nucleosides | |
US8933052B2 (en) | Uracyl spirooxetane nucleosides | |
EP2166016A1 (en) | Phosphoramidate Derivatives of Nucleosides |